Expand test portfolio Genomic Health has a strong Oncotype DX legacy with extensive adoption (750,000+ patients across 90+ countries) and is expanding into liquid and tissue-based tests, such as Oncotype SEQ Liquid Select, presenting cross-sell opportunities to existing oncology customers and new partners in liquid biopsy.

Strategic partnerships Past and prospective collaborations (MDxHealth asset sales and co-development in oncology) indicate a favorable environment for joint ventures, licensing, or distribution partnerships to broaden geographic reach and accelerate access to new genomic tests and services.

Multi-cancer applicability Oncotype DX suite covers breast, colon, and prostate cancers with genomic scores that influence treatment decisions, suggesting sales opportunities to expand into additional cancer types and integrate with multidisciplinary care teams seeking genomics-guided treatment planning.

Data-driven selling The Oncotype IQ Genomic Intelligence Platform highlights a data-centric value proposition; there is a sales angle in offering analytics-driven decision support to clinicians and payers, emphasizing outcome optimization and potential to reduce overtreatment.

Global reach & scale With international presence and a history of large-scale deployment, Genomic Health can pursue global expansion strategies, target top oncology centers, and leverage existing international networks to accelerate uptake of new tests and companion diagnostics.